Immune Checkpoint

On the mechanism of anti-CD39 immune checkpoint therapy
David Allard, Bertrand Allard, John Stagg

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000186; DOI: 10.1136/jitc-2019-000186
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline, Hongtao Liu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 175; DOI: 10.1186/s40425-019-0611-3
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
Thiago Vidotto, Sarah Nersesian, Charles Graham, D. Robert Siemens, Madhuri Koti

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 148; DOI: 10.1186/s40425-019-0619-8
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
Joe Yeong, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Clara Chong Hui Ong, Aye Aye Thike, Wei Hseun Yeap, Yi Yang, Ansel Yi Herh Lim, Timothy Kwang Yong Tay, Jin Liu, Siew-Cheng Wong, Jinmiao Chen, Elaine Hsuen Lim, Jabed Iqbal, Rebecca Dent, Evan W. Newell, Puay Hoon Tan

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 34; DOI: 10.1186/s40425-019-0499-y
A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment
Yu-Tzu Liu, Tai-Chung Tseng, Ruey-Shyang Soong, Chun-Yi Peng, Yu-Hsing Cheng, Shiu-Feng Huang, Tsung-Hsien Chuang, Jia-Horng Kao, Li-Rung Huang

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 144; DOI: 10.1186/s40425-018-0462-3
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Andrew Hantel, Brooke Gabster, Jason X. Cheng, Harvey Golomb, Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 73; DOI: 10.1186/s40425-018-0384-0
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
Randy F. Sweis, Yuanyuan Zha, Lomax Pass, Brian Heiss, Tara Chongsuwat, Jason J. Luke, Thomas F. Gajewski, Russell Szmulewitz

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 24; DOI: 10.1186/s40425-018-0334-x
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 8; DOI: 10.1186/s40425-018-0316-z
Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter, Gerold Schuler, Lucie Heinzerling

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 2; DOI: 10.1186/s40425-017-0309-3
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky, Christian Grommes

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 99; DOI: 10.1186/s40425-017-0302-x

Main menu

Immune Checkpoint

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immune Checkpoint

Pages